Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2022-04-26 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
《股东大会议事规则》2022年4月修订
Governance Information Classification · 95% confidence The document is titled as the "Shareholders' Meeting Rules" of a company, detailing the procedures, powers, and regulations governing the shareholders' meetings. It includes sections on the general provisions, convening, proposals, voting, resolutions, and records of shareholders' meetings. It is a governance document outlining internal rules and procedures rather than a report of financial results, audit, or announcements of voting results. It does not contain financial statements or earnings data, nor is it a transcript or presentation. It is not an announcement or notice but a detailed governance framework document. Therefore, it fits best under Governance Information (CGR). The document length is substantial and contains detailed governance rules, supporting this classification with high confidence.
2022-04-26 Chinese
关于董事、监事、高级管理人员2021年薪酬的确认及2022年薪酬方案
Remuneration Information Classification · 95% confidence The document is an announcement regarding the confirmation of 2021 remuneration and the 2022 remuneration plan for the company's directors, supervisors, and senior management. It includes detailed salary figures and adjustments but does not contain full financial statements or comprehensive financial performance data. The focus is on remuneration information for top executives and directors, which matches the description of Remuneration Information filings. The document is not an annual report, audit report, or management report, nor is it a regulatory filing or announcement of a report. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2022-04-26 Chinese
年度募集资金使用情况专项说明
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised through a public stock issuance by the company 赛隆药业集团股份有限公司 for the year 2021. It includes specifics on the amount raised, usage of funds, surplus funds, project progress, and compliance with regulatory requirements. The content focuses on the status and application of the raised capital, including investment projects, fund storage, and approvals by the board and shareholders. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not a full annual report or audit report, nor is it a brief announcement or a certification. It is a substantive report on fundraising and capital usage for a specific fiscal year, fitting the CAP category.
2022-04-26 Chinese
2021年年度审计报告
Regulatory Filings
2022-04-26 Chinese
2021年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2021 年度财务决算报告' which translates to '2021 Annual Financial Settlement Report'. It contains detailed financial data for the full year 2021, including revenue, net profit, assets, liabilities, cash flow, and comparative figures from 2020. The document is about 3145 characters long, which is relatively short but contains substantive financial data and analysis rather than just an announcement or a link to a report. The content includes comprehensive financial statements and management discussion of financial results for the full fiscal year, consistent with an Annual Report. There is no indication that this is merely an announcement or a certification letter. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-26 Chinese
《对外担保管理制度》2022年4月修订
Governance Information Classification · 95% confidence The document is titled '赛隆药业集团股份有限公司 对外担保管理制度' which translates to 'Sailong Pharmaceutical Group Co., Ltd. External Guarantee Management System'. It is a detailed internal policy document outlining the rules, procedures, responsibilities, and disclosure requirements related to the company's external guarantees. It references relevant laws and regulations, describes approval processes involving the board and shareholders, and details risk management and disclosure obligations. There is no indication that this is a financial report, earnings release, or announcement of voting results. It is not a regulatory filing or announcement but rather a governance or management policy document. Given the content focuses on internal rules and governance practices related to external guarantees, the most appropriate classification is Governance Information (CGR). The document length (6216 characters) and detailed procedural content support this classification with high confidence.
2022-04-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.